New Risk • Apr 24
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 9.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.6x net interest cover). Negative equity (-UK£9.5m). Minor Risks Share price has been volatile over the past 3 months (9.9% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (UK£30.8m market cap, or US$41.5m). Reported Earnings • Nov 27
First half 2026 earnings released: EPS: UK£0.005 (vs UK£0.009 loss in 1H 2025) First half 2026 results: EPS: UK£0.005 (up from UK£0.009 loss in 1H 2025). Revenue: UK£57.2m (down 6.1% from 1H 2025). Net income: UK£367.0k (up UK£1.02m from 1H 2025). Profit margin: 0.6% (up from net loss in 1H 2025). Revenue is forecast to grow 4.7% p.a. on average during the next 3 years, compared to a 11% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has increased by 60% per year, which means it is tracking significantly ahead of earnings growth. Aankondiging • Nov 17
Carclo plc to Report First Half, 2026 Results on Nov 21, 2025 Carclo plc announced that they will report first half, 2026 results on Nov 21, 2025 Aankondiging • Sep 27
Carclo plc Appoints Ian Tichias as a Director Carclo plc in the AGM held on September 26 approved the appointment of Ian Tichias as a Director. New Risk • Sep 01
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 6.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.5x net interest cover). Negative equity (-UK£12m). Minor Risks Share price has been volatile over the past 3 months (6.4% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (UK£34.8m market cap, or US$47.1m). Board Change • Sep 01
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Natalia Kozmina was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Aankondiging • Aug 29
Carclo plc, Annual General Meeting, Sep 26, 2025 Carclo plc, Annual General Meeting, Sep 26, 2025. Location: the offices of addleshaw goddard llp, milton gate, 60 chiswell street, ec1y 4ag, london United Kingdom Aankondiging • Aug 28
Carclo plc to Report Fiscal Year 2025 Results on Aug 29, 2025 Carclo plc announced that they will report fiscal year 2025 results at 6:00 AM, Coordinated Universal Time on Aug 29, 2025 New Risk • Jun 23
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 18% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported September 2024 fiscal period end). Share price has been volatile over the past 3 months (8.9% average weekly change). Market cap is less than US$100m (UK£35.1m market cap, or US$47.1m). New Risk • Apr 24
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 18% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.9% average weekly change). Market cap is less than US$100m (UK£20.3m market cap, or US$27.0m). Reported Earnings • Dec 09
First half 2025 earnings released: UK£0.008 loss per share (vs UK£0.03 loss in 1H 2024) First half 2025 results: UK£0.008 loss per share (improved from UK£0.03 loss in 1H 2024). Revenue: UK£61.0m (down 8.9% from 1H 2024). Net loss: UK£607.0k (loss narrowed 72% from 1H 2024). Revenue is forecast to grow 9.7% p.a. on average during the next 3 years, compared to a 3.5% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 96 percentage points per year, which is a significant difference in performance. Aankondiging • Nov 12
Carclo plc to Report First Half, 2025 Results on Dec 05, 2024 Carclo plc announced that they will report first half, 2025 results on Dec 05, 2024 Aankondiging • Jul 31
Carclo plc, Annual General Meeting, Sep 05, 2024 Carclo plc, Annual General Meeting, Sep 05, 2024. Location: the templars suite, novotel london blackfriars, 46 blackfriars road, se1 8nz, london United Kingdom Reported Earnings • Jul 19
Full year 2024 earnings released: UK£0.045 loss per share (vs UK£0.054 loss in FY 2023) Full year 2024 results: UK£0.045 loss per share (improved from UK£0.054 loss in FY 2023). Revenue: UK£132.7m (down 7.5% from FY 2023). Net loss: UK£3.30m (loss narrowed 17% from FY 2023). Revenue is forecast to grow 2.4% p.a. on average during the next 3 years, compared to a 6.9% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 85 percentage points per year, which is a significant difference in performance. Aankondiging • Jul 16
Carclo plc to Report Q4, 2024 Results on Jul 18, 2024 Carclo plc announced that they will report Q4, 2024 results at 6:00 AM, Coordinated Universal Time on Jul 18, 2024 New Risk • Jul 08
New major risk - Revenue and earnings growth Earnings have declined by 5.8% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.7x net interest cover). Share price has been highly volatile over the past 3 months (23% average weekly change). Earnings have declined by 5.8% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Market cap is less than US$100m (UK£14.3m market cap, or US$18.3m). New Risk • Jun 17
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.7x net interest cover). Share price has been highly volatile over the past 3 months (23% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Market cap is less than US$100m (UK£13.6m market cap, or US$17.2m). Price Target Changed • May 14
Price target decreased by 62% to UK£0.25 Down from UK£0.65, the current price target is provided by 1 analyst. New target price is 100% above last closing price of UK£0.13. Stock is up 14% over the past year. The company posted a net loss per share of UK£0.054 last year. Board Change • May 14
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Non-Executive Director Rachel Amey was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Aankondiging • Apr 17
Carclo plc Announces Appointment of Natalia Kozmina as Non-Executive Director, Member of the Audit and Risk, Remuneration, and Nomination Committees and Chair of the Remuneration Committee Carclo plc announced that Natalia Kozmina will be appointed as a Non-Executive Director of the Board with effect from 22 April 2024. Natalia will be a member of the Audit and Risk, Remuneration, and Nomination Committees and will chair the Remuneration Committee from 1 May 2024. Natalia has a wealth of cross-functional experience gained in large multi-national organizations across a number of industries. Most recently, Natalia was Chief Human Resources and ESG Stewardship Officer for Convatec Group, a FTSE 100 global medical products and technology company. Prior to this she held senior human resources roles in Iron Mountain and Smiths Group. Natalia started her career in the biopharmaceutical industry with Abbott Laboratories, where she spent more than 10 years in a number of sales & marketing and management positions, culminating in her appointment as General Manager, Established Products Division, UK and Ireland. Over the course of her career, Natalia has gained deep expertise in business transformations and turnarounds and brings rich experience of leading global customer-centric businesses through rapid scale up, large-scale M&A and spin-o?s, operating in complex, highly regulated industries. Aankondiging • Feb 28
Carclo plc Announces Resignation of Jonathan (Jon) Templeman as Non-Executive Director Carclo plc announced that Jonathan (Jon) Templeman has resigned as a Non-Executive Director of the Company, effective 27 February 2024. Aankondiging • Feb 16
Carclo plc Announces Strategic Closure of its Tucson, AZ Facility Carclo plc announced the strategic closure of its Tucson, AZ facility. This decision represents the culmination of US restructuring efforts, aimed at optimizing operational footprint and aligning closely with strategic objectives. In alignment with this closure, Carclo is taking significant steps to enhance operational efficiency and customer service. The majority of manufacturing volumes from the Tucson site are being relocated to its facilities in Pennsylvania, USA. This move not only consolidates technical and manufacturing expertise but also brings production closer to Design & Engineering center, fostering innovation and efficiency. Furthermore, Carclo is leveraging its global footprint to redistribute manufacturing capacity. This strategic reallocation is designed to position production facilities closer to customer bases, thereby improving service levels, reducing lead times, and facilitating more sustainable operations. Carclo is committed to supporting them through comprehensive transition assistance programs for the employees affected, including job placement services, counselling, and career transition resources. Aankondiging • Jan 29
Carclo plc Appoints Jonathan (Jon) Templeman as Non-Executive Director, Effective from 1 February 2024 Carclo plc announced that Jonathan (Jon) Templeman will be appointed as a Non-Executive Director of the Board with effect from 1 February 2024. Jon will be a member of the Audit and Risk, Remuneration, and Nomination Committees and Senior Independent Director. Jon has a wealth of turnaround and business growth experience, gained leading a number of international, industrial businesses. Jon is currently Non-Executive Chair of Whittan Group Ltd, a manufacturer and seller of steel storage equipment. Prior to this, Jon was Chief Executive Officer of Whittan Group from 2017 to June 2023, Chief Executive Officer of Bridon Group from 2009 to 2016 and, before that, various roles at EASB Global including Chief Executive Officer from 2003 to 2009. Prior to joining EASB Global, Jon held a number of roles at PricewaterhouseCoopers. Board Change • Jan 25
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Interim Senior Independent Director Rachel Amey was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Aankondiging • Nov 17
Carclo plc to Report Q2, 2024 Results on Nov 30, 2023 Carclo plc announced that they will report Q2, 2024 results at 7:00 AM, GMT Standard Time on Nov 30, 2023 Aankondiging • Oct 26
Carclo Strategic Decision to Close Derry Facility Carclo plc announced a strategic decision to cease operations at its US Derry NH facility. The facility, acquired in 2016 with the aim of expanding toolmaking capabilities, was transitioned into an injection moulding shop catering for short run business for diverse markets. After careful evaluation and a comprehensive review of the Group's strategy, Carclo has determined that the short run business and its associated projects do not align with the company's long-term strategic vision and as such the decision to close the Derry facility was reached. The one-time expenses associated with the facility closure are estimated to total £0.8 million (including asset write offs, inventory and fixed assets), with a cash outflow of £0.2 million. These costs are integral to the execution of transition plan. The strategic move is expected to result in annualized savings of approximately £0.4 million in unadjusted EBIT (uEBIT). To support affected employees during this transition, Carclo is implementing a comprehensive employee support plan. This focusses on job placement assistance and access to counselling and career transition resources. Customers and suppliers who have been partners with the Derry NH facility will receive specific communications regarding the closure. Carclo is committed to addressing their concerns and ensuring a smooth transition for all ongoing contracts and arrangements. This decision aligns Carclo's operations with its core strategy of factory specialization, process standardization, operational excellence, financial stability, and sustainability. New Risk • Oct 20
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: UK£7.84m (US$9.53m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.4x net interest cover). Earnings have declined by 4.0% per year over the past 5 years. Market cap is less than US$10m (UK£7.84m market cap, or US$9.53m). Aankondiging • Aug 01
Carclo plc, Annual General Meeting, Aug 31, 2023 Carclo plc, Annual General Meeting, Aug 31, 2023, at 10:30 Coordinated Universal Time. Location: Addleshaw Goddard LLP, Milton Gate, 60 Chiswell Street, London, EC1Y 4AG London United Kingdom Reported Earnings • Jul 14
Full year 2023 earnings released: UK£0.054 loss per share (vs UK£0.07 profit in FY 2022) Full year 2023 results: UK£0.054 loss per share (down from UK£0.07 profit in FY 2022). Revenue: UK£143.4m (up 12% from FY 2022). Net loss: UK£3.96m (down 178% from profit in FY 2022). Over the last 3 years on average, earnings per share has remained flat but the company’s share price has increased by 9% per year, which means it is well ahead of earnings. Aankondiging • Jun 22
Carclo plc to Report Fiscal Year 2023 Results on Jul 12, 2023 Carclo plc announced that they will report fiscal year 2023 results at 6:00 AM, Coordinated Universal Time on Jul 12, 2023 Board Change • Mar 10
Less than half of directors are independent There are 4 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. 2 independent directors (3 non-independent directors). Non-Executive Chair Joe Oatley is the most experienced director on the board, commencing their role in 2018. Independent Non-Executive Director Rachel Amey was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors. Board Change • Mar 02
Less than half of directors are independent There are 4 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. 2 independent directors (3 non-independent directors). Independent Non-Executive Chair Joe Oatley is the most experienced director on the board, commencing their role in 2018. Senior Independent Director Eric Hutchinson was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors. Reported Earnings • Dec 01
First half 2023 earnings released: EPS: UK£0.009 (vs UK£0.065 in 1H 2022) First half 2023 results: EPS: UK£0.009 (down from UK£0.065 in 1H 2022). Revenue: UK£72.2m (up 23% from 1H 2022). Net income: UK£668.0k (down 86% from 1H 2022). Profit margin: 0.9% (down from 8.2% in 1H 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 1.5% growth forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 70% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth. Price Target Changed • Nov 16
Price target decreased to UK£0.44 Down from UK£0.65, the current price target is provided by 1 analyst. New target price is 183% above last closing price of UK£0.16. Stock is down 64% over the past year. The company posted earnings per share of UK£0.07 last year. Price Target Changed • Jul 14
Price target decreased to UK£0.45 Down from UK£0.63, the current price target is provided by 1 analyst. New target price is 113% above last closing price of UK£0.21. Stock is down 53% over the past year. The company posted earnings per share of UK£0.07 last year. Reported Earnings • Jul 01
Full year 2022 earnings released: EPS: UK£0.07 (vs UK£0.085 in FY 2021) Full year 2022 results: EPS: UK£0.07 (down from UK£0.085 in FY 2021). Revenue: UK£128.6m (up 20% from FY 2021). Net income: UK£5.11m (down 18% from FY 2021). Profit margin: 4.0% (down from 5.8% in FY 2021). Over the next year, revenue is expected to shrink by 4.1% compared to a 16% decline forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 109% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Buying Opportunity • Jun 22
Now 22% undervalued after recent price drop Over the last 90 days, the stock is down 15%. The fair value is estimated to be UK£0.30, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company has become profitable. Buying Opportunity • Jun 07
Now 20% undervalued after recent price drop Over the last 90 days, the stock is down 3.0%. The fair value is estimated to be UK£0.30, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company has become profitable. Buying Opportunity • May 03
Now 22% undervalued after recent price drop Over the last 90 days, the stock is down 33%. The fair value is estimated to be UK£0.30, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company has become profitable. Board Change • Apr 27
High number of new and inexperienced directors There are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. Senior Independent Non-Executive Director Joe Oatley is the most experienced director on the board, commencing their role in 2018. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Nov 21
First half 2022 earnings released: EPS UK£0.065 (vs UK£0.018 loss in 1H 2021) The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2022 results: Revenue: UK£58.7m (up 18% from 1H 2021). Net income: UK£4.79m (up UK£6.12m from 1H 2021). Profit margin: 8.2% (up from net loss in 1H 2021). Over the last 3 years on average, earnings per share has increased by 66% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings. Price Target Changed • Sep 03
Price target increased to UK£0.63 Up from UK£0.53, the current price target is provided by 1 analyst. New target price is 43% above last closing price of UK£0.44. Stock is up 245% over the past year. Reported Earnings • Jul 02
Full year 2021 earnings released: EPS UK£0.085 (vs UK£0.026 loss in FY 2020) The company reported a decent full year result with improved earnings and profit margins, although revenues were weaker. Full year 2021 results: Revenue: UK£107.6m (down 2.7% from FY 2020). Net income: UK£6.21m (up UK£8.11m from FY 2020). Profit margin: 5.8% (up from net loss in FY 2020). Over the last 3 years on average, earnings per share has fallen by 47% per year but the company’s share price has only fallen by 20% per year, which means it has not declined as severely as earnings. Executive Departure • May 04
Independent Non-Executive Director has left the company On the 30th of April, David Toohey's tenure as Independent Non-Executive Director ended after 6.1 years in the role. We don't have any record of a personal shareholding under David's name. A total of 4 executives have left over the last 12 months. Executive Departure • Apr 03
Independent Non-Executive Director has left the company On the 31st of March, Peter Slabbert's tenure as Independent Non-Executive Director ended after 6.0 years in the role. As of December 2020, Peter personally held only 30.00k shares (UK£4.9k worth at the time). A total of 3 executives have left over the last 12 months. Is New 90 Day High Low • Mar 01
New 90-day high: UK£0.25 The company is up 81% from its price of UK£0.14 on 01 December 2020. The British market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 13% over the same period. Is New 90 Day High Low • Feb 03
New 90-day high: UK£0.21 The company is up 16% from its price of UK£0.18 on 05 November 2020. The British market is up 12% over the last 90 days, indicating the company outperformed over that time. However, its price trend is similar to the Chemicals industry, which is also up 16% over the same period. Is New 90 Day High Low • Feb 02
New 90-day high: UK£0.20 The company is up 16% from its price of UK£0.18 on 04 November 2020. The British market is up 13% over the last 90 days, indicating the company outperformed over that time. However, its price trend is similar to the Chemicals industry, which is also up 16% over the same period. Reported Earnings • Nov 28
First half 2021 earnings released: UK£0.018 loss per share The company reported a poor first half result with increased losses and weaker revenues and control over expenses. First half 2021 results: Revenue: UK£50.0m (down 11% from 1H 2020). Net loss: UK£1.32m (loss widened 284% from 1H 2020). Over the last 3 years on average, earnings per share has fallen by 65% per year but the company’s share price has only fallen by 52% per year, which means it has not declined as severely as earnings.